Oslo, 7 May 2026 - Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results